Call the infoline 800.452.2873
Browse Store
Search
Prepared by Dr. Brian G.M. Durie, the IMF's Concise Review of the Disease and Treatment Options provides an in-depth overview of myeloma, with a discussion of the epidemiology, pathophysiology, clinical features, treatment options, and new and emerging treatments. This information is helpful to health professionals and patients alike.
FREE 
 
The IMF Info Pack provides comprehensive information on treatment options and disease management. Available free of charge, the Info Pack includes The IMF Patient Handbook , as well as many of the important Understanding Series booklets. Click on the thumbnail to the left to see a complete list of the publications included in the Info Pack.
FREE 
 
The Patient Handbook provides a basic understanding of myeloma to allow patients to make informed decisions about treatment choices.
FREE 
Clinical trials are research studies of new treatments that involve patients. Whether or not to participate in a clinical trial is one of the critical decisions you and your oncologist may have to make at some point in the cancer care continuum.
FREE 
 
Darzalex® (daratumumab) is a laboratory-made monoclonal antibody that targets a specific single protein on the surface of myeloma cells.
FREE 
 
After reading this booklet, you should know what dexamethasone is, how it works, possible side effects, and more.
FREE 
 
Empliciti® (elotuzumab) is the first immunostimulatory monoclonal antibody approved for the treatment of myeloma. Empliciti enlists immune system cells to attack myeloma. Before reading this booklet, it may be helpful to read another IMF publication, Understanding the Immune System in Myeloma.
FREE 
 
Farydak is the first histone deacetylase (HDAC) inhibitor approved for use in treating myeloma. Farydak is taken in capsule form in combination with Velcade® (bortezomib) and dexamethasone. by patients who have already been treated with Vel¬cade and an immunomodulatory drug.
FREE 
 
Myeloma patients may experience fatigue caused by the disease, by treatment, and by the understandable anxiety and/or depression that affects many. This booklet contains a thorough examination of coping strategies and causes of myeloma fatigue, as well as suggestions for discussing fatigue with your doctor.
FREE 
 
High-dose therapy with stem cell rescue, or "stem cell transplant," is an important treatment option for eligible patients with multiple myeloma.
FREE 
 
This booklet discusses Kyprolis?, the results of clinical trials with Kyprolis, how and when it is administered, its possible side effects, and how to manage them.
FREE 
 
Ninlaro® (ixazomib) is the first oral proteasome inhibitor approved by the FDA to treat myeloma. Ninlaro is the third drug in the proteasome inhibitor class that has been approved for myeloma. It is indicated for myeloma patients who have received at least one prior therapy.
FREE 
 
Pomalyst in combination with dexamethasone was approved by the U.S. Food and Drug Administration (FDA) on February 8, 2013 for relapsed and refractory myeloma.
FREE 
 
Revlimid? (lenalidomide) has been approved by the FDA for use in myeloma.
FREE 
 
Using thalidomide to treat myeloma is a new idea, but thalidomide itself has been studied for many decades. Much has been learned about how thalidomide works in the treatment of different diseases, and how its side effects can be treated.
FREE 
 
This booklet will help you understand immune system basics. The immune system is extremely complex. It is made up of multiple mechanisms that work together to protect and defend the human body from external threats such as bacteria, viruses, and toxins, and from internal threats such as cancer.
FREE 
 
This booklet is focused on therapies given to patients with myeloma bone involvement. Bisphosphonate therapy is not treatment for myeloma, but it does help to prevent skeletal complications of myeloma. Monoclonal antibody therapy targets a protein which controls bone regeneration and remodeling.
FREE 
 
As treatment for myeloma improves and patients live longer, it is important to reduce the disability that can result from the painful problem of vertebral compression fractures, which occur when the vertebra collapses or fractures because the bone is too weak to withstand the pressure or stress placed upon it.
FREE 
 
This booklet covers the basics of FDA approved VELCADE?, including how it works, how it is administered, how is it used in clinical practice today, and side effects.
FREE